COMMUNIQUÉS West-GlobeNewswire

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
08/06/2026
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England [...]
Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, Montreal
08/06/2026
Canadian ophthalmic device company presents interventional glaucoma portfolio, launches digital presence, and invites surgeons to a hands-on OBi™ Core and OBi™ Gon dry lab at the COS Annual Meeting in Montreal DIEPPE, [...]
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
08/06/2026
CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1 FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug [...]
Capricor Therapeutics to Present at Upcoming Investor Conferences
08/06/2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior [...]
Sharecare to honor extraordinary nurses through The DAISY Foundation’s global recognition program
08/06/2026
Nurses at Sharecare now eligible to be nominated for The DAISY Award for Extraordinary Nurses® by patients, their families, and colleagues, with honorees selected twice per year ATLANTA, June 08, 2026 (GLOBE NEWSWIRE [...]
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
08/06/2026
Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
08/06/2026
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE [...]
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
08/06/2026
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis Late-breaking [...]
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
08/06/2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE [...]
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08/06/2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, [...]
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
08/06/2026
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of [...]
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
08/06/2026
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regression LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd. (“Engitix”), a biotechnology company [...]
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
08/06/2026
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data [...]
Virbac : Déclaration d'actions et de droits de vote 05/2026
08/06/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Standard BioTools and Treeline Biosciences Announce Merger Agreement
08/06/2026
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co- [...]
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
08/06/2026
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a [...]
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
08/06/2026
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U. [...]

Pages